“Thank you for reaching out again regarding the AIPAC-003 trial....

  1. 2,841 Posts.
    lightbulb Created with Sketch. 412
    “Thank you for reaching out again regarding the AIPAC-003 trial. I understand your concern, however, we are prioritising our lung cancer phase 3 trial because it provides Immutep with the biggest opportunity for success, given the size of the addressable market and data we have generated for efti in combination with Keytruda, the world's top selling drug.Unfortunately, we have limited resources and are not able to develop efti as rapidly in all the indications that we believe it has potential, including breast cancer.Immutep completed patient enrolment in the randomised Phase II portion of the AIPAC trial in late 2024. A further update for AIPAC-003 is expected towards the end of this calendar year. We will provide more details as soon as we have them.Kind regards”,Deanne
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
26.0¢
Change
-0.010(3.70%)
Mkt cap ! $381.6M
Open High Low Value Volume
27.5¢ 27.5¢ 26.0¢ $159.6K 602.9K

Buyers (Bids)

No. Vol. Price($)
12 254280 26.0¢
 

Sellers (Offers)

Price($) Vol. No.
26.5¢ 85840 5
View Market Depth
Last trade - 16.10pm 01/08/2025 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.